Arbutus Biopharma Corporation

(NASDAQ:ABUS)

Latest On Arbutus Biopharma Corporation (ABUS):

Date/Time Type Description Signal Details
2023-05-18 02:45 ESTNewsArbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023N/A
2023-05-04 21:46 ESTNewsArbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:45 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67MN/A
2023-04-25 14:16 ESTNewsArbutus sheds 18% after FDA clinical hold on antiviralN/A
2023-04-12 00:01 ESTNewsModerna wins appeals court ruling in Arbutus COVID vaccine patent disputeN/A
2023-04-05 02:46 ESTNewsPfizer, BioNTech dip as Arbutus charges violation of COVID vaccine patentsN/A
2023-03-02 12:31 ESTNewsArbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88MN/A
2023-03-02 12:30 ESTNewsArbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 22:16 ESTNewsArbutus Biopharma FY 2022 Earnings PreviewN/A
2023-02-23 11:16 ESTNewsArbutus Biopharma Corp.: Long Road Ahead For HBV CureN/A
2022-11-09 19:33 ESTNewsArbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23MN/A
2022-11-09 19:32 ESTNewsArbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 19:32 ESTNewsArbutus trades higher as Q3 net loss narrows, revenue grows on license dealN/A
2022-11-07 14:15 ESTNewsArbutus Biopharma (ABUS) presents at AASLD 2022 - SlideshowN/A
2022-11-03 05:01 ESTNewsArbutus gains after court denies Moderna motion to dismiss Covid-19 royalties caseN/A
2022-09-12 13:02 ESTNewsArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'N/A
2022-08-30 16:31 ESTNewsArbutus stock rises on US patent linked to hepatitis B therapy AB-729N/A
2022-08-04 22:47 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47MN/A
2022-08-04 22:46 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 16:46 ESTNewsArbutus Biopharma Q2 2022 Earnings PreviewN/A
2022-07-20 18:00 ESTNewsArbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trialN/A
2022-06-30 05:46 ESTNewsArbutus: 2 Key Catalysts To Look Forward To After EASL Data ReleaseN/A
2022-06-06 15:46 ESTNewsArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentN/A
2022-05-05 20:18 ESTNewsArbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16MN/A
2022-05-05 20:16 ESTNewsArbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 21:31 ESTNewsArbutus Biopharma Q1 2022 Earnings PreviewN/A
2022-03-19 19:34 ESTNewsArbutus sued to avoid patent dispute over Pfizer/BioNTech COVID-19 shotN/A
2022-03-14 23:02 ESTNewsArbutus price target raised at H.C. Wainwright on upcoming data readoutsN/A
2022-03-08 08:32 ESTNewsArbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestN/A
2022-03-04 00:32 ESTNewsArbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35MN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 12:45 ESTNewsArbutus Biopharma Q4 2021 Earnings PreviewN/A
2022-03-01 02:17 ESTNewsModerna hit by lawsuit as Arbutus, Genevant seek damages for use of COVID-19 vaccine patentsN/A
2022-01-24 16:17 ESTNewsArbutus Biopharma outlines milestones for 2022N/A
2021-12-22 11:31 ESTNewsRoivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy ArbutusN/A
2021-12-17 17:31 ESTNewsArbutus Biopharma: How Will Patent Win Impact Stock Outlook?N/A
2021-12-13 14:32 ESTNewsArbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%N/A
2021-12-08 01:33 ESTNewsArbutus identifies molecular targets for COVID-19 treatmentN/A
2021-12-01 16:46 ESTNewsModerna loses patent fight against Arbutus related to vaccines; Arbutus up 40%N/A
2021-12-01 16:46 ESTNewsArbutus chronic hepatitis B virus treatment shows antiviral activity in early-stage trialN/A
2021-12-01 16:46 ESTNewsRoivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%N/A
2021-11-20 03:16 ESTNewsArbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive InvestmentN/A
2021-11-19 06:32 ESTNewsAlnylam, Arrowhead gain on Novo bid to acquire DicernaN/A
2021-11-05 00:18 ESTNewsArbutus Biopharma EPS in-line, beats on revenueN/A
2021-11-05 00:16 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 03:02 ESTNewsArbutus Biopharma Q3 2021 Earnings PreviewN/A
2021-10-09 16:30 ESTNewsA look at the biopharmas developing new treatments for liver diseasesN/A
2021-10-07 03:30 ESTNewsModerna slips ahead of legal battle to invalidate COVID-19 vaccine patentsN/A
2021-09-22 20:29 ESTNewsArbutus Biopharma (ABUS) Investor Presentation - SlideshowN/A

About Arbutus Biopharma Corporation (ABUS):

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Quotes by TradingView

See Advanced Chart

General

  • Name Arbutus Biopharma Corporation
  • Symbol ABUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 76
  • Last Split Factor1:5
  • Last Split Date2010-11-04
  • Fiscal Year EndDecember
  • IPO Date2015-08-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arbutusbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.69
  • Price/Book (Most Recent Quarter) 2.44
  • Enterprise Value Revenue 56.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.86
  • Next Year EPS Estimate -$0.67
  • Next Quarter EPS Estimate -$0.23
  • Operating Margin -828%
  • Return on Assets -30%
  • Return on Equity -73%
  • Revenue 6.91 million
  • Earnings Per Share -$1.79
  • Revenue Per Share $0.09
  • Gross Profit -40567000
  • Quarterly Earnings Growth 47.5%
View More

Highlights

  • Market Capitalization 349.26 million
  • EBITDA -71643000
  • PE Ratio -9.48
  • Analyst Target Price $6.11
  • Book Value Per Share $1.23
View More

Share Statistics

  • Shares Outstanding 95.58 million
  • Shares Float 69.81 million
  • % Held by Insiders 2123%
  • % Held by Institutions 30.96%
  • Shares Short 3.27 million
  • Shares Short Prior Month 2.55 million
  • Short Ratio 0.94
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 3.05
  • 52 Week High $6.48
  • 52 Week Low $0.88
  • 50 Day Moving Average 3.96
  • 200 Day Moving Average 3.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arbutus Biopharma Corporation (ABUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arbutus Biopharma Corporation (ABUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$2.39 million-$0.23-$0.22-2.74%
2020-09-302020-11-05$N/A-$0.27-$0.22-26.07%
2020-06-302020-08-07$N/A-$0.25-$0.24-1.59%
2020-03-312020-05-11$1.49 million-$0.25-$0.3120.71%
2019-12-312020-03-05$1.62 million-$0.46-$0.36-26.6%
2019-09-302019-11-06$3.06 million-$1.50-$0.34-346.17%
2019-06-302019-08-05$653000-$0.46-$0.38-22.19%
2019-03-312019-05-06$679000-$0.47-$0.32-46.41%
2018-12-312019-03-07$1.68 million-$0.37-$0.406.98%
2018-09-302018-11-07$1.59 million-$0.49-$0.41-19.75%
2018-06-302018-08-02$1.24 million$0.01-$0.39102.54%
2018-03-312018-05-03$1.44 million-$0.36-$0.4010.76%
2017-12-312018-03-14$2.53 million-$0.67-$0.38-73.97%
2017-09-302017-11-02$6.89 million-$0.21-$0.3540.78%
2017-06-302017-08-03$1.04 million-$0.33-$0.4221.27%
2017-03-312017-05-04$235000-$0.34-$0.30-12.68%
2016-12-312017-03-21$-195000-$4.08-$0.40-932.74%
2016-09-302016-11-03$774000-$0.37-$0.5025.5%
2016-06-302016-08-04$309000-$2.47-$0.39-528.02%
2016-03-312016-05-04$603000-$0.31-$0.3716.46%
2015-12-312016-03-09$15.26 million-$0.10-$0.3974.17%
2015-09-302015-11-05$4.07 million-$0.12-$0.2958.62%
2015-06-302015-08-07$869000-$0.27-$0.296.9%
2015-03-312015-05-06$4.68 million-$0.40-$0.36-11.11%
2014-12-312015-03-12$4.35 million-$0.27-$0.283.57%
2014-09-302014-11-06$4.36 million-$0.39-$0.31-25.81%
2014-06-302014-08-13$1.81 million-$0.28-$0.25-12%
2014-03-312014-05-14$4.43 million-$0.91$0.16-668.75%
2013-12-312014-03-06$7.51 million-$0.10$0.06-266.67%
2013-09-302013-11-13$2.96 million-$0.42-$0.21-100%
2013-06-302013-08-12$2.79 million-$0.21
2013-03-312013-05-14$2.16 million-$0.18
2012-12-312013-03-27$3.91 million$2.70
2012-09-302012-11-13$3.1 million-$0.25
2012-06-302012-08-14$3.56 million-$0.14-$0.1612.5%
2012-03-312012-05-15$3.6 million-$0.25-$0.17-47.06%
2011-12-312012-03-27$3.66 million-$0.15
2011-09-302011-11-08$3.96 million-$0.12-$0.3060%
2011-06-302011-08-11$4.58 million-$0.33-$0.30-10%
2011-03-312011-05-10$4.48 million-$0.30-$0.3616.67%
2010-12-312011-03-30$6.21 million-$0.20-$0.2520%
2010-09-302010-11-15$4.34 million-$1.09-$0.20-445%
2010-06-302010-08-12$2.18 million-$0.40-$0.35-14.29%
2009-12-312010-03-17$4.27 million-$0.25-$0.3016.67%
2009-06-302009-08-12$3.25 million-$0.20-$0.15-33.33%
2009-03-312009-05-13$2.28 million-$0.20-$0.2520%
2008-12-312009-03-24$2.53 million-$0.35-$0.5030%
2007-12-312008-03-30$4.22 million$0.10$0.05100%
2007-09-302007-11-14$5.76 million$0.30$0.45-33.33%
2007-06-302007-08-08$2.82 million-$1.05-$0.30-250%

Arbutus Biopharma Corporation (ABUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arbutus Biopharma Corporation (ABUS) Chart:

Arbutus Biopharma Corporation (ABUS) News:

Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arbutus Biopharma Corporation (ABUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-06-1813.44CALL0 8485.07TRUE00
2026-06-1822.43CALL0 33272.92TRUE00
2026-06-1831.43CALL0 540TRUE00
2026-06-1840.7CALL0 20310TRUE00
2026-06-1850.1CALL0 146553.04FALSE00
2026-06-1860.05CALL0 1058125.07FALSE00
2026-06-1870.1CALL0 141175.95FALSE00
2026-06-1880.05CALL0 22196.88FALSE00
2026-06-1890CALL0 0329.12FALSE00
2026-06-18100CALL0 1355.67FALSE00
2026-06-1810.03PUT0 10699.56FALSE00
2026-06-1820.05PUT0 2397.31FALSE00
2026-06-1830PUT0 0174.8FALSE00
2026-06-1840.05PUT0 329476.39FALSE00
2026-06-1850.95PUT0 189066.07TRUE00
2026-06-1861.8PUT0 0108.58TRUE00
2026-06-1870PUT0 0159.63TRUE00
2026-06-1880PUT0 00TRUE00
2026-06-1890PUT0 00TRUE00
2026-06-18100PUT0 00TRUE00
2026-07-1713.3CALL0 1292.23TRUE00
2026-07-1722.25CALL0 0191.26TRUE00
2026-07-1730CALL0 077.46TRUE00
2026-07-1740CALL0 052.68TRUE00
2026-07-1750.2CALL1 22359.94FALSE0.20
2026-07-1760CALL0 0120.11FALSE00
2026-07-1770CALL0 0157.75FALSE00
2026-07-1780CALL0 0145.12FALSE00
2026-07-1710PUT0 0444.16FALSE00
2026-07-1720PUT0 0252.17FALSE00
2026-07-1730PUT0 0137.54FALSE00
2026-07-1740PUT0 099.13FALSE00
2026-07-1750PUT0 059.95TRUE00
2026-07-1760PUT0 048.95TRUE00
2026-07-1770PUT0 0100.56TRUE00
2026-07-1780PUT0 00TRUE00
2026-09-1813.4CALL0 2245.62TRUE00
2026-09-1820CALL0 00TRUE00
2026-09-1831.5CALL0 61983.24TRUE00
2026-09-1841.1CALL1 155365.93TRUE0.060.06
2026-09-1850.41CALL0 19664.29FALSE00
2026-09-1860.25CALL31 355.72FALSE0.250
2026-09-1870CALL0 0101.74FALSE00
2026-09-1880CALL0 0116.68FALSE00
2026-09-1890CALL0 1129.03FALSE00
2026-09-1810PUT0 0347.77FALSE00
2026-09-1820PUT0 0195.46FALSE00
2026-09-1830PUT0 1119.96FALSE00
2026-09-1840PUT0 150077.17FALSE00
2026-09-1850PUT0 059.4TRUE00
2026-09-1860PUT0 059.57TRUE00
2026-09-1870PUT0 050.45TRUE00
2026-09-1880PUT0 071.9TRUE00
2026-09-1890PUT0 082.9TRUE00
2026-12-1810CALL0 00TRUE00
2026-12-1820CALL0 084.83TRUE00
2026-12-1831.75CALL3 072.29TRUE1.750
2026-12-1840CALL0 070.66TRUE00
2026-12-1850.7CALL0 2057.62FALSE00
2026-12-1860CALL0 077.91FALSE00
2026-12-1870CALL0 090.63FALSE00
2026-12-1880CALL0 093.97FALSE00
2026-12-1810PUT0 0294.23FALSE00
2026-12-1820PUT0 0162.97FALSE00
2026-12-1830PUT0 089.72FALSE00
2026-12-1840PUT0 073.37FALSE00
2026-12-1850PUT0 059.07TRUE00
2026-12-1860PUT0 062.36TRUE00
2026-12-1870PUT0 065.88TRUE00
2026-12-1880PUT0 057.98TRUE00
2027-01-1510CALL0 00TRUE00
2027-01-152.50CALL0 570TRUE00
2027-01-1531.91CALL0 1873.07TRUE00
2027-01-153.51.85CALL0 36156.48TRUE00
2027-01-1541.15CALL6 43167.75TRUE1.150
2027-01-154.51.35CALL1 9669.24FALSE1.350
2027-01-1550.8CALL0 14074.95FALSE00
2027-01-155.50.6CALL0 67965.86FALSE00
2027-01-1570.25CALL0 36267.31FALSE00
2027-01-1580CALL0 095.48FALSE00
2027-01-15100.24CALL0 80106.11FALSE00
2027-01-1510PUT0 0276.12FALSE00
2027-01-152.50PUT0 0189.79FALSE00
2027-01-1530PUT0 109100.91FALSE00
2027-01-153.50PUT0 683.4FALSE00
2027-01-1540.68PUT0 20197.65FALSE00
2027-01-154.50PUT0 11161.85TRUE00
2027-01-1550.95PUT0 14257.62TRUE00
2027-01-155.50PUT0 12348.45TRUE00
2027-01-1570PUT0 670TRUE00
2027-01-1580PUT0 00TRUE00
2027-01-15100PUT0 00TRUE00

Latest ABUS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST400$2.39
Jun 13, 2022 7:59 PM EST200$2.39
Jun 13, 2022 7:59 PM EST1000$2.39
Jun 13, 2022 7:59 PM EST200$2.385
Jun 13, 2022 7:59 PM EST17$2.385

Arbutus Biopharma Corporation (ABUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1447028/000000000019016815/0000000000-19-016815-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000089542120000423/0000895421-20-000423-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000089924319019548/0000899243-19-019548-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000004/0000903423-19-000004-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000012/0000903423-19-000012-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000288/0000903423-19-000288-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000298/0000903423-19-000298-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000299/0000903423-19-000299-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583619000122/0000935836-19-000122-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583620000133/0000935836-20-000133-index.htm
2018-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000104746918007755/0001047469-18-007755-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746919002498/0001047469-19-002498-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746920002560/0001047469-20-002560-index.htm
2018-12-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074106/0001104659-18-074106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074112/0001104659-18-074112-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919006779/0001104659-19-006779-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919008025/0001104659-19-008025-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919023074/0001104659-19-023074-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919030387/0001104659-19-030387-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040421/0001104659-19-040421-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040422/0001104659-19-040422-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040589/0001104659-19-040589-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040594/0001104659-19-040594-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040598/0001104659-19-040598-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040934/0001104659-19-040934-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919045102/0001104659-19-045102-index.htm
2019-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919059987/0001104659-19-059987-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919070902/0001104659-19-070902-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465920020447/0001104659-20-020447-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000110465920100169/0001104659-20-100169-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001084/0001123292-18-001084-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001085/0001123292-18-001085-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001115/0001123292-18-001115-index.htm
2018-12-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001125/0001123292-18-001125-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/0001123292-19-000431-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000432/0001123292-19-000432-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000435/0001123292-19-000435-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000436/0001123292-19-000436-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000437/0001123292-19-000437-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000438/0001123292-19-000438-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000910/0001123292-19-000910-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000911/0001123292-19-000911-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034587/0001144204-19-034587-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034595/0001144204-19-034595-index.htm
2018-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006281/0001171843-18-006281-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006907/0001171843-18-006907-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007089/0001171843-18-007089-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007727/0001171843-18-007727-index.htm
2018-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318008152/0001171843-18-008152-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319001586/0001171843-19-001586-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319002996/0001171843-19-002996-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004042/0001171843-19-004042-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004412/0001171843-19-004412-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319005142/0001171843-19-005142-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184320007636/0001171843-20-007636-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193243/0001193125-19-193243-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193262/0001193125-19-193262-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000120919119041996/0001209191-19-041996-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000006/0001447028-19-000006-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000010/0001447028-19-000010-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000015/0001447028-19-000015-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000018/0001447028-19-000018-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/0001447028-19-000025-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000031/0001447028-19-000031-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000049/0001447028-19-000049-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000050/0001447028-19-000050-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000051/0001447028-19-000051-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000052/0001447028-19-000052-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000053/0001447028-19-000053-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/0001447028-19-000054-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000055/0001447028-19-000055-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000056/0001447028-19-000056-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000057/0001447028-19-000057-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000060/0001447028-19-000060-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000064/0001447028-19-000064-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000069/0001447028-19-000069-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000071/0001447028-19-000071-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000144702819000078/0001447028-19-000078-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000081/0001447028-19-000081-index.htm
2020-01-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000004/0001447028-20-000004-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000006/0001447028-20-000006-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000009/0001447028-20-000009-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000024/0001447028-20-000024-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000025/0001447028-20-000025-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000026/0001447028-20-000026-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/0001447028-20-000027-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000028/0001447028-20-000028-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000029/0001447028-20-000029-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000030/0001447028-20-000030-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000031/0001447028-20-000031-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000035/0001447028-20-000035-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000038/0001447028-20-000038-index.htm
2020-03-0610-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000041/0001447028-20-000041-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000043/0001447028-20-000043-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000046/0001447028-20-000046-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000049/0001447028-20-000049-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000052/0001447028-20-000052-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/0001447028-20-000063-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000064/0001447028-20-000064-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000065/0001447028-20-000065-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000066/0001447028-20-000066-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000067/0001447028-20-000067-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000068/0001447028-20-000068-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000069/0001447028-20-000069-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000071/0001447028-20-000071-index.htm
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000078/0001447028-20-000078-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000100/0001447028-20-000100-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/0001447028-20-000118-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000121/0001447028-20-000121-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000124/0001447028-20-000124-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000126/0001447028-20-000126-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000129/0001447028-20-000129-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000135/0001447028-20-000135-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000140/0001447028-20-000140-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000143/0001447028-20-000143-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000144/0001447028-20-000144-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000150/0001447028-20-000150-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315219001945/0001493152-19-001945-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315220002406/0001493152-20-002406-index.htm
2018-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-08-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001171/0001567619-18-001171-index.htm
2018-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003916/0001567619-18-003916-index.htm
2018-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003919/0001567619-18-003919-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004374/0001567619-18-004374-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004376/0001567619-18-004376-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004378/0001567619-18-004378-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004380/0001567619-18-004380-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/0001628280-18-013909-index.htm
2020-01-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520000069/9999999995-20-000069-index.htm
2020-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520002943/9999999995-20-002943-index.htm
2020-07-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004141/9999999997-20-004141-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004563/9999999997-20-004563-index.htm

Arbutus Biopharma Corporation (ABUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-23Michael J. McElhaughChief Business OfficerSell20,000.005.01100,200.001,367,457.00https://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2018-08-13Michael J. SofiaChief Scientific OfficerSell4,250.009.5140,435.781,499,153.00https://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-11-28Mark J. MurrayDirectorBuy25,000.001.3533,750.00341,396.00https://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm